Hemp Research — Page 158

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

Protocol of a Combined Cohort and Cross-Sectional Study of Persons Receiving Medical Cannabis in Florida, USA: The Medical Marijuana and Me (M3) Study (2023)

Significant knowledge gaps regarding the effectiveness and safety of medical cannabis (MC) create clinical challenges for MC physicians, making treatment recommendations and patients choosing treatment among the growing number of options offered in dispensaries. Additionally, data describing the characteristics of people who use MC and the products and doses they receive are lacking. The Medical Marijuana and Me (M<sup>3</sup>) Study was designed to collect patient-centered data from MC users. W

RECONSTRUCCIÓN DE SITUACIONES DIDÁCTICAS DE MATEMÁTICAS EN EL AULA. UN ESTUDIO EN PREESCOLAR (2020)

El artículo se centra en las transformaciones que docentes imprimen a situaciones didácticas de matemáticas asociadas a un enfoque didáctico sociocontructivista. Se estudia el caso de dos educadoras trabajando con el tema de Tratamiento de la Información en preescolar. Metodológicamente, consideramos este estudio una Ingeniería Didáctica de Desarrollo (Perrin-Glorian, 2011). El análisis se realizó desde una doble perspectiva teórica: las situaciones didácticas se caracterizan y analizan desde la

The therapeutic use of cannabis and cannabinoids (2022)

Cannabinoids mainly target the endocannabinoid system, which emerges as a potentially interesting therapeutical target due to its major role in modulating key biological processes throughout the body. As such, cannabinoids have already been proposed as, for example, anti-emetics, antispasticity agents, appetite stimulants, anti-epileptic, analgesic, depressants of intraocular pressure or as agents to control movement disorders in Tourette syndrome. Here, we reviewed the research evidence availab

Dravet syndrome: novel insights into SCN1A-mediated epileptic neurodevelopmental disorders within the molecular diagnostic-therapeutic framework (2025)

Dravet Syndrome (DS), a rare genetic encephalopathy characterized by severe drug-resistant epilepsy and progressive neurodevelopmental regression in infancy, is caused by <i>de novo</i> mutations in the <i>SCN1A</i> gene on chromosome 2q24 in over 80% of cases. This review synthesizes current insights into its molecular pathogenesis, precision diagnostics, and therapeutic innovations: <i>SCN1A</i> mutations disrupt Nav1.1 sodium channel expression and membrane trafficking in GABAergic interneuro

Differential effects of antiseizure medications on neurogenesis: Evidence from cells to animals (2024)

Neurogenesis, the process of generating functionally integrated neurons from neural stem and progenitor cells, is involved in brain development during embryonic stages but continues throughout life. Adult neurogenesis plays essential roles in many brain functions such as cognition, brain plasticity, and repair. Abnormalities in neurogenesis have been described in many neuropsychiatric and neurological disorders, including epilepsy. While sharing a common property of suppressing seizures, accumul

Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation (2024)

Neuroinflammation can be caused by disease, aging, infection, brain injury, toxicity, or stress. It is a contributory factor in the neuropathology of serious conditions that include multiple sclerosis (MS), Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and autoimmune encephalomyelitis (EAE). The neuroinflammatory response involves the activation of microglia, astrocytes, the endothelial cells of the blood-brain barrier, and peripherally-derived immune cells. The

Potential of Heterogeneous Compounds as Antidepressants: A Narrative Review (2022)

Depression is a globally widespread disorder caused by a complicated interplay of social, psychological, and biological factors. Approximately 280 million people are suffering from depression worldwide. Traditional frontline antidepressants targeting monoamine neurotransmitters show unsatisfactory effects. The development and application of novel antidepressants for dissimilar targets are on the agenda. This review characterizes the antidepressant effects of multiple endogenous compounds and/or

Women With Genetic Epilepsies (2025)

Some epilepsy syndromes are more common in female individuals. Often, these syndromes have an underlying genetic variant involving the X chromosome that is typically lethal in male individuals, resulting in a higher female prevalence. However, some of the idiopathic generalized epilepsies such as juvenile myoclonic epilepsy are conditions with complex inheritance, with thousands of variants in genes throughout the genome. But they can also have a predominance in female individuals. In this study

CPD: Crowd-based Pothole Detection (2019)

In spite of the publication of some 7,000 scientific articles on cannabis, doubt and confusion about the effects of cannabis still exist.These are largely due to the fact that the drugs obtained from the cannabis plant are very complex and variable substances and this variability is often either not understood or neglected.The failure to take account of this variability often devalues the result of investigations into the pharmacological and toxicological effects of the drug.Meaningful experimen

Unveiling the Potential of Phytocannabinoids: Exploring Marijuana’s Lesser-Known Constituents for Neurological Disorders (2024)

Cannabis sativa is known for producing over 120 distinct phytocannabinoids, with Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC) and cannabidiol (CBD) being the most prominent, primarily in their acidic forms. Beyond Δ<sup>9</sup>-THC and CBD, a wide array of lesser-known phytocannabinoids, along with terpenes, flavonoids, and alkaloids, demonstrate diverse pharmacological activities, interacting with the endocannabinoid system (eCB) and other biological pathways. These compounds, charact

Integrative Oncology’s 30-Year Anniversary: What Have We Achieved? A North American Naturopathic Oncology Perspective (2023)

In 1991 the U.S. Congress mandated that the National Institutes of Health (NIH) form the Office of Alternative Medicine to study alternative medical therapies, especially in oncology care. Shortly after, the National Cancer Institute (NCI) created its own division of complementary and alternative medicine (Office of Complementary and Alternative Medicine). At the genesis of the field 30 years ago, what were we hoping to see accomplished by now? In this article we take a look back at milestones,

Common practical questions – and answers – at the British Association for Psychopharmacology child and adolescent psychopharmacology course (2022)

The British Association for Psychopharmacology course on child and adolescent psychopharmacology has been run for more than 20 years and is currently a very popular course, attracting around 140 delegates/year from across the United Kingdom and abroad. As Faculty of recent sessions of the course, we have selected the most common questions we have been asked in recent years and provided evidence-based and/or expert-informed answers. We have included 27 questions and answers related to attention-d

Pathogenic in-Frame Variants in SCN8A: Expanding the Genetic Landscape of SCN8A-Associated Disease (2021)

Numerous <i>SCN8A</i> mutations have been identified, of which, the majority are <i>de novo</i> missense variants. Most mutations result in epileptic encephalopathy; however, some are associated with less severe phenotypes. Mouse models generated by knock-in of human missense <i>SCN8A</i> mutations exhibit seizures and a range of behavioral abnormalities. To date, there are only a few <i>Scn8a</i> mouse models with in-frame deletions or insertions, and notably, none of these mouse lines exhibit

Roadmap to advance therapeutics for SYNGAP1-related disorder: a patient organization perspective from SynGAP Research Fund (2025)

<i>SYNGAP1</i>-related disorder (SRD) is a developmental and epileptic encephalopathy caused by a disruption of the <i>SYNGAP1</i> gene. At the beginning of 2024, it is one of many rare monogenic brain disorders without disease-modifying treatments, but that is changing. This article chronicles the last 5 years, beginning when treatments for SRD were not publicly in development, to the start of 2024 when many SRD-specific treatments are advancing. We discuss the progress across many realms that

A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways (2024)

Sturge-Weber syndrome (SWS) is a rare congenital neurocutaneous disorder typically caused by a somatic mosaic mutation in R183Q <i>GNAQ</i>. At-risk children present at birth with a capillary malformation port-wine birthmark. The primary diagnostic characteristic of the disorder includes leptomeningeal enhancement of the brain, which demonstrates abnormal blood vessels and results in impaired venous drainage and impaired local cerebral perfusion. Impaired cerebral blood flow is complicated by se

Hippocampal Cb2 receptors: an untold story (2021)

The field of cannabinoid research has been receiving ever-growing interest. Ongoing debates worldwide about the legislation of medical cannabis further motivates research into cannabinoid function within the central nervous system (CNS). To date, two well-characterized cannabinoid receptors exist. While most research has investigated Cb<sub>1</sub> receptors (Cb<sub>1</sub>Rs), Cb<sub>2</sub> receptors (Cb<sub>2</sub>Rs) in the brain have started to attract considerable interest in recent years.